Andrey Y. Zaritskey

2 Akkuratova Str
Saint Petersburg, SPE 197341, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.

Journal: Pathophysiology : the official journal of the International Society for Pathophysiology

Published: May 05, 2023

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.

Journal: Frontiers in immunology

Published: September 20, 2021

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.

Journal: Hematological oncology

Published: January 11, 2021

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report.

Journal: BMC women's health

Published: November 16, 2020

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.

Journal: Leukemia

Published: May 15, 2020

CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia

CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia

Journal: Molekuliarnaia biologiia

Published: February 21, 2020

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Journal: Leukemia

Published: February 10, 2020

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.

Journal: Biology

Published: December 26, 2019

Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes.

Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes.

Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Published: September 11, 2019

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

Journal: British journal of haematology

Published: August 13, 2019

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Journal: Leukemia

Published: March 28, 2019

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.

Journal: Terapevticheskii arkhiv

Published: February 01, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026